19-Nov-2024	Cyclopharm Bell Potter Healthcare Conference Presentation

3-Oct-2024	CYC Signs Agreement with VA and First DoD Order Received

1-Oct-2024	Change of Director's Interest Notice - JW

3-Sep-2024	Cyclopharm - 2024 First Half Results & USA Expansion Update

29-Aug-2024	Webinar - 1H2024 Results and USA update

27-Aug-2024	Cyclopharm 2024 H1 Trading and USA Expansion Update

27-Aug-2024	Half Yearly Report and Accounts

28-Jun-2024	Cleansing Notice

28-Jun-2024	Application for quotation of securities - CYC

28-Jun-2024	Proposed issue of securities - CYC

28-Jun-2024	Change of Director's Interest Notice - KB

28-Jun-2024	Change of Director's Interest Notice - DH

28-Jun-2024	Change of Director's Interest Notice - DA

28-Jun-2024	Application for quotation of securities - CYC

27-Jun-2024	Appendix 3B

27-Jun-2024	Update - Proposed issue of securities - CYC

25-Jun-2024	Update - Proposed issue of securities - CYC

25-Jun-2024	Cyclopharm completes oversubscribed Share Purchase Plan

24-Jun-2024	USA Reimbursement Update for TECHNEGAS

19-Jun-2024	Cyclopharm Presenting at Macquarie Emerging Leaders Conf

11-Jun-2024	Change in substantial holding AACCF

11-Jun-2024	Change in substantial holding Chemical Overseas

11-Jun-2024	Change in substantial holding Barings

5-Jun-2024	Change in substantial holding from CVC

5-Jun-2024	TECHNEGAS Awarded US Pass-Through Reimbursemt Status

4-Jun-2024	Cleansing Statement - Placement

4-Jun-2024	Update - Application for quotation of securities - CYC

4-Jun-2024	CYC Results of AGM Poll - Addendum

3-Jun-2024	Change of Director's Interest Notice - GK

3-Jun-2024	Change in substantial holding

31-May-2024	Share Purchase Plan Offer Booklet

30-May-2024	Update - Application for quotation of securities - CYC

30-May-2024	Cleasing Statement - Placement

29-May-2024	Change of Director's Interest Notice - JW

29-May-2024	Application for quotation of securities - CYC

29-May-2024	CYC Results of AGM poll amended

27-May-2024	Notification of buy-back - CYC

27-May-2024	CYC Results of AGM poll

27-May-2024	Update - Proposed issue of securities - CYC

27-May-2024	Managing Director's AGM address

27-May-2024	CYC 2024 AGM Presentation

27-May-2024	Chairman's Address to Shareholders

27-May-2024	Cyclopharm Successfully Completes A$20.0 Million Placement

24-May-2024	Proposed issue of securities - CYC

24-May-2024	Cyclopharm Capital Raising

24-May-2024	Cyclopharm Capital Raising Presentation

24-May-2024	Trading Halt

16-May-2024	Appendix 3C Final buy-back notification

6-May-2024	Cyclopharm Business Update

26-Apr-2024	Becoming a substantial holder

26-Apr-2024	Notice of Annual General Meeting/Proxy Form

24-Apr-2024	Ceasing to be a substantial holder

8-Apr-2024	Application for quotation of securities - CYC

26-Mar-2024	Appendix 4G

26-Mar-2024	Annual Report to shareholders

25-Mar-2024	Voluntary Escrow Shares to be Released

25-Mar-2024	Date of Annual General Meeting

19-Mar-2024	First USA Patients Imaged with Technegas

1-Mar-2024	S&P DJI Announces March 2024 Quarterly Rebalance

28-Feb-2024	CYC Results Summary

28-Feb-2024	Preliminary Final Report

19-Feb-2024	CYC Board Changes

19-Feb-2024	Initial Director's Interest Notice

12-Feb-2024	Cyclopharm Appoints Jason Smith as CFO

6-Feb-2024	Cyclopharm to Present at Euroz Hartleys Healthcare Forum

5-Feb-2024	Cyclopharm Trading and USA Launch Update

29-Jan-2024	CYC and Yale Translational Research Partner on Technegas

5-Dec-2023	Cyclopharm Signs First USA Contract for Technegas

1-Dec-2023	Change of Director's Interest Notice

1-Dec-2023	Application for quotation of securities - CYC

15-Nov-2023	Technegas USA Commercialisation Update

2-Nov-2023	Change of Director's Interest Notice

1-Nov-2023	Change of Director's Interest Notice

5-Oct-2023	CYC USFDA Approval Webinar Presentation

3-Oct-2023	FDA Technegas Approval Webinar

3-Oct-2023	SNMMI Announcement Regarding USFDA Approval of Technegas

2-Oct-2023	Cyclopharm Receives USFDA Approval for Technegas

26-Sep-2023	Investor Presentation Correction

26-Sep-2023	Investor Presentation Correction

12-Sep-2023	Application for quotation of securities - CYC

25-Aug-2023	Litigation Update and Receipt of Settlement Payment

22-Aug-2023	Dividend/Distribution - CYC

22-Aug-2023	Half Year Accounts

9-Aug-2023	USFDA Approval Process Update

17-Jul-2023	Cyclopharm 2023 Half Year Accounts Update - Record Revenues

16-May-2023	Notification of buy-back - CYC

16-May-2023	Results of Meeting

16-May-2023	Managing Director's Address to Shareholders

16-May-2023	CYC 2023 AGM Presentation

16-May-2023	Chairman's Address to Shareholders

9-May-2023	Cyclopharm Confirms USFDA Scheduled Inspection Date

24-Apr-2023	USFDA Confirms Technegas Six Month Review Period

20-Apr-2023	Cyclopharm Acquires DuPharma ApS

18-Apr-2023	Application for quotation of securities - CYC

17-Apr-2023	Proposed issue of securities - CYC

13-Apr-2023	Notice of Annual General Meeting/Proxy Form

5-Apr-2023	Cyclopharm USFDA Approval Progress Update

31-Mar-2023	Appendix 4G

31-Mar-2023	Annual Report to shareholders

30-Mar-2023	Technegas Enters Final Six Month USFDA Review Cycle

24-Mar-2023	Application for quotation of securities - CYC

15-Mar-2023	Date of Annual General Meeting

20-Feb-2023	CYC Results Summary

20-Feb-2023	Preliminary Final Report

20-Feb-2023	Dividend/Distribution - CYC

5-Dec-2022	Change of Director's Interest Notice - KBarrow

30-Nov-2022	Change of Director's Interest Notice - DAngus

29-Nov-2022	Cyclopharm Receives $1.64m R&D Refund

9-Nov-2022	Bell Potter Healthcare Conference Directors Profile

9-Nov-2022	Bell Potter Healthcare Conference

5-Oct-2022	Notification of cessation of securities - CYC

27-Sep-2022	CYC Board Changes

27-Sep-2022	Initial Director's Interest Notice

1-Sep-2022	Initial Director's Interest Notice

1-Sep-2022	CYC Board Changes

17-Aug-2022	Half Year 2022 Results

17-Aug-2022	Half Yearly Report and Accounts

17-Aug-2022	Dividend/Distribution - CYC

7-Jul-2022	Technegas Used In Multicenter COVID Study

4-Jul-2022	1H 2022 Business Update - Record Revenues

14-Jun-2022	Change of Director's Interest Notice

24-May-2022	CYC Investor Presentation 24 May 2022

24-May-2022	Technegas used in Diagnosing Long COVID

23-May-2022	Change of Director's Interest Notice

17-May-2022	Results of Meeting

17-May-2022	Managing Director's Address to Shareholders

17-May-2022	CYC 2022 AGM Presentation

17-May-2022	Chairman's Address to Shareholders

14-Apr-2022	Notice of Annual General Meeting/Proxy Form

31-Mar-2022	Appendix 4G

31-Mar-2022	Annual Report to shareholders

16-Mar-2022	Date of Annual General Meeting

9-Mar-2022	Change of Director's Interest Notice

4-Mar-2022	S&P DJI Announces March 2022 Quarterly Rebalance

23-Feb-2022	CYC Results Summary

23-Feb-2022	Dividend/Distribution - CYC

23-Feb-2022	Preliminary Final Report

3-Feb-2022	Cyclopharm USFDA Update

24-Jan-2022	Cyclopharm Business Update

1-Dec-2021	Final Director's Interest Notice

1-Dec-2021	Board Update

9-Nov-2021	Bell Potter HealthCare Conference

28-Oct-2021	Jobkeeper Payments Notice

23-Aug-2021	Half Year 2021 Financial Results

23-Aug-2021	Dividend/Distribution - CYC

23-Aug-2021	Half Yearly Report and Accounts

10-Aug-2021	Initial Director's Interest Notice

10-Aug-2021	CYC Board Changes

2-Jul-2021	CYC First Half Trading Update

28-Jun-2021	Cyclopharm USFDA Update

7-Jun-2021	Ceasing to be a substantial holder from MUFG

4-Jun-2021	Ceasing to be a substantial holder from MS

4-Jun-2021	Becoming a substantial holder from MUFG

4-Jun-2021	Becoming a substantial holder from MS

3-Jun-2021	Ceasing to be a substantial holder from MUFG

2-Jun-2021	Ceasing to be a substantial holder from MS

1-Jun-2021	Becoming a substantial holder from MUFG

31-May-2021	Becoming a substantial holder from MS

26-May-2021	Ceasing to be a substantial holder from MUFG

25-May-2021	Ceasing to be a substantial holder from MS

24-May-2021	Becoming a substantial holder from MUFG

21-May-2021	Becoming a substantial holder from MS

20-May-2021	Ceasing to be a substantial holder from MUFG

20-May-2021	Ceasing to be a substantial holder from MS

19-May-2021	Becoming a substantial holder from MUFG

18-May-2021	Becoming a substantial holder from MS

18-May-2021	Ceasing to be a substantial holder from MUFG

18-May-2021	Ceasing to be a substantial holder from MS

13-May-2021	Becoming a substantial holder from MUFG

13-May-2021	Becoming a substantial holder from MS

11-May-2021	Ceasing to be a substantial holder from MUFG

10-May-2021	Ceasing to be a substantial holder from MS

7-May-2021	Becoming a substantial holder from MUFG

6-May-2021	Ceasing to be a substantial holder from MUFG

5-May-2021	Becoming a substantial holder from MS

4-May-2021	CYC Amended Constitution

4-May-2021	Results of Meeting

4-May-2021	Becoming a substantial holder from MUFG

4-May-2021	Ceasing to be a substantial holder from MUFG

4-May-2021	Managing Director's Address to Shareholders

4-May-2021	CYC 2021 AGM Presentation

4-May-2021	Chairman's Address to Shareholders

3-May-2021	Ceasing to be a substantial holder from MS

30-Apr-2021	Becoming a substantial holder from MS

29-Apr-2021	Ceasing to be a substantial holder from MS

20-Apr-2021	Becoming a substantial holder from MUFG

19-Apr-2021	Becoming a substantial holder from MS

19-Apr-2021	Ceasing to be a substantial holder from MUFG

16-Apr-2021	Ceasing to be a substantial holder from MS

15-Apr-2021	Becoming a substantial holder from MUFG

14-Apr-2021	Becoming a substantial holder from MS

30-Mar-2021	Notice of Annual General Meeting/Proxy Form

29-Mar-2021	Appendix 4G

29-Mar-2021	Annual Report to shareholders

26-Mar-2021	Change of Share Registry Details

12-Mar-2021	S&P DJI Announces March 2021 Quarterly Rebalance

12-Mar-2021	Confirmation of Technegas USFDA Timetable

8-Mar-2021	Change of Director's Interest Notice - DH

3-Mar-2021	Change of Director's Interest Notice - TM

3-Mar-2021	Date of Annual General Meeting

25-Feb-2021	CYC Results Summary

25-Feb-2021	Preliminary Final Report

25-Feb-2021	Dividend/Distribution - CYC

24-Feb-2021	Change of Director's Interest Notice DH

24-Feb-2021	Change of Director's Interest Notice TM

19-Feb-2021	Appendix 2A LTIP

19-Feb-2021	Appendix 2A SPP

17-Feb-2021	Appendix 3B - Amended

17-Feb-2021	Cyclopharm Announces Results of Share Purchase Plan Offer

10-Feb-2021	Change in substantial holding - Chemical Overseas

10-Feb-2021	Change in substantial holding - Barings

8-Feb-2021	Change in substantial holding

5-Feb-2021	Cyclopharm Receives $3.1M R&D Tax Incentive for FY2020

4-Feb-2021	Change in substantial holding from CVC

3-Feb-2021	Change of substantial shareholding from AEF

1-Feb-2021	Share Purchase Plan Offer Booklet

1-Feb-2021	Appendix 2A - Placement

1-Feb-2021	Cleansing Notice - Share Purchase Plan

1-Feb-2021	Cleansing Notice - Placement

29-Jan-2021	Change in substantial holding

29-Jan-2021	Change in substantial shareholding from AEF

25-Jan-2021	Proposed issue of Securities - CYC

25-Jan-2021	Cyclopharm Capital Raising Presentation

25-Jan-2021	Cyclopharm Successfully Completes A$30 Million Placement

22-Jan-2021	SNMMI Requests USFDA to Expedite Approval For Technegas

21-Jan-2021	Trading Halt

14-Jan-2021	USFDA Approval Progress for Technegas and Business Update

26-Nov-2020	Bell Potter Healthcare Conference

22-Oct-2020	Change of Director's Interest Notice TM

1-Oct-2020	Change of Director's Interest Notice

29-Sep-2020	Change of Director's Interest Notice

23-Sep-2020	Cyclopharm Investor Presentation

15-Sep-2020	Technegas USA Trial Successfully Meets Primary Endpoint

9-Sep-2020	CYC Partners With McMasters University In COVID-19 Research

25-Aug-2020	Half Year 2020 Financial Results

25-Aug-2020	Half Yearly Report and Accounts

25-Aug-2020	Dividend/Distribution - CYC

27-Jul-2020	Change of Director's Interest Notice

27-Jul-2020	Appendix 2A

9-Jul-2020	Results of Meeting

9-Jul-2020	Managing Director's Address to Shareholders

9-Jul-2020	CYC 2020 AGM Presentation

9-Jul-2020	Chairman's Address to Shareholders

7-Jul-2020	CYC 1H2020 Business Update

5-Jun-2020	Notice of Annual General Meeting/Proxy Form

29-May-2020	Technegas Approved in Russia - Clarification

27-May-2020	USFDA Approval to File Received for Technegas

26-May-2020	Technegas Approved in Russia

21-May-2020	Final share buy-back notice - Appendix 3F

6-May-2020	Form 484 cancellation of Long Term Incentive Plan shares

5-May-2020	Appendix 2A

14-Apr-2020	USFDA Grants Cyclopharm USD$2.9m Application Fee Waiver

31-Mar-2020	CYC Appendix 4G

31-Mar-2020	Annual Report to shareholders

30-Mar-2020	Cyclopharm Lodges NDA for Technegas with the USFDA

24-Mar-2020	Cyclopharm Company Update

17-Mar-2020	Change of Director's Interest Notice

17-Mar-2020	Change of Director's Interest Notice

13-Mar-2020	Change of Director's Interest Notice

3-Mar-2020	Cyclopharm Investor Presentation

2-Mar-2020	Change of Director's Interest Notice

26-Feb-2020	Preliminary Final Report

26-Feb-2020	Dividend/Distribution - CYC

15-Jan-2020	Change in substantial holding

15-Jan-2020	Change in substantial holding

13-Jan-2020	Change in substantial holding

3-Jan-2020	Becoming a substantial holder

2-Jan-2020	Change in substantial holding from CVC

2-Jan-2020	Change in substantial holding from AEF

31-Dec-2019	Becoming a substantial holder

31-Dec-2019	Appendix 3B

30-Dec-2019	Change of Director's Interest Notice

20-Dec-2019	CYC Institutional Placement - Premium To Share Price

20-Dec-2019	AGREEMENT TO UTILISE CYCLOTRON FACILITY ASSETS

19-Dec-2019	Trading Halt

19-Dec-2019	Pause in Trading

19-Dec-2019	Appendix 3B

12-Dec-2019	Change of Director's Interest Notice JM

12-Dec-2019	Appendix 3B

10-Dec-2019	CYC Business Update

27-Nov-2019	Final Director's Interest Notice

27-Nov-2019	Board Update

21-Oct-2019	Cyclopharm Investor Presentation - TechKnow Invest Roadshow

30-Sep-2019	Cyclopharm Strengthens Leadership Team

22-Aug-2019	CYC Half Yearly Reports and Accounts

22-Aug-2019	Dividend/Distribution - CYC

26-Jul-2019	Cyclopharm Investor Presentation - Bioshares 2019

27-Jun-2019	Change of Director's Interest Notice - TM

13-Jun-2019	Change of Director's Interest Notice - TM

31-May-2019	Appendix 3B LTIP

27-May-2019	Change of Director's Interest Notice

27-May-2019	Appendix 3B

21-May-2019	Announcement of buy-back - Appendix 3C

21-May-2019	Results of Meeting

21-May-2019	Managing Director's Address to Shareholders

21-May-2019	CYC 2019 AGM Presentation

21-May-2019	Chairman's Address to Shareholders

20-May-2019	Final share buy-back notice - Appendix 3F

18-Apr-2019	Notice of General Meeting/Proxy Form

4-Apr-2019	Cyclopharm Investor Presentation

3-Apr-2019	Change of Director's Interest Notice

29-Mar-2019	CYC Appendix 4G

29-Mar-2019	Annual Report to shareholders

27-Feb-2019	Dividend/Distribution - CYC

27-Feb-2019	Preliminary Final Report

24-Jan-2019	CYC Update - R&D Tax Incentive, USFDA, German Litigation

19-Dec-2018	CANM Endorses Technegas

29-Oct-2018	CYC - FNN Interview

12-Oct-2018	Positive USFDA Meeting - Technegas sales expected in 2019

9-Oct-2018	CYC Form 484 Cancellation of Long Term Incentive Plan shares

17-Sep-2018	Change of Director's Interest Notice VG

17-Sep-2018	Response to ASX Appendix 3Y Query

12-Sep-2018	Change of Director's Interest Notice VG

4-Sep-2018	Cyclopharm FNN Investor Event

23-Aug-2018	Dividend/Distribution - CYC

23-Aug-2018	CYC Half Yearly Reports and Accounts

13-Aug-2018	Change in substantial holding from CVC

10-Aug-2018	Change in substantial holding from AEF

8-Aug-2018	Cyclopharm 2018 First Half Preliminary Headline Update

2-Jul-2018	Appendix 3B LTIP

28-Jun-2018	Change of Director's Interest Notice

27-Jun-2018	Change of Director's Interest Notice - Amended

26-Jun-2018	Change of Director's Interest Notice

14-Jun-2018	Change in substantial holding from CVC

13-Jun-2018	Change in substantial holding from AEF

29-May-2018	Announcement of buy-back - Appendix 3C

29-May-2018	Results of Meeting

29-May-2018	CYC 2018 AGM Presentation

29-May-2018	Managing Director's Address to Shareholders

29-May-2018	Chairman's Address to Shareholders

28-May-2018	Final share buy-back notice - Appendix 3F

17-May-2018	Better Defining Airways Disease with Technegas

7-May-2018	Cyclopharm Acquires Scandinavian Distribution Business

27-Apr-2018	Notice of Annual General Meeting/Proxy Form

29-Mar-2018	40 Patient Milestone Achieved For Technegas USFDA Trial

26-Mar-2018	CYC Appendix 4G

26-Mar-2018	Annual Report to shareholders

15-Mar-2018	2017 Results Presentation

1-Mar-2018	Change of Director's Interest Notice - David Heaney

26-Feb-2018	CYC Reports Solid FY2017 Results - Maintains Dividend

26-Feb-2018	Preliminary Final Report

26-Feb-2018	Dividend/Distribution - CYC

21-Dec-2017	FNN Interview and Presentation

12-Dec-2017	Cyclopharm FNN Investor Event

20-Nov-2017	Change of Director's Interest Notice - D Heaney

18-Oct-2017	CYC CEO Presentation 2017 Australian Microcap Conference

26-Sep-2017	Technegas USFDA Clinical Trial - Patient Enrolment Underway

20-Sep-2017	Cyclopharm acquires European distribution business

19-Sep-2017	Advancing Molecular Imaging in NSW

8-Sep-2017	Form 484 - cancellation of Long Term Incentive Plan shares

28-Aug-2017	Cyclopharm Limited 1H2017 Results Investor Presentation

28-Aug-2017	Dividend/Distribution - CYC

18-Aug-2017	Nuclear imaging trial aiming to clear up airway diagnosis

21-Jul-2017	CYC CEO To Present at Bioshares 2017 Biotech Conference

6-Jul-2017	Change in substantial holding - Chemical Trustee Limited

6-Jul-2017	Change in substantial holding - Barings Acceptance Limited

4-Jul-2017	Change in substantial holding from CVC

4-Jul-2017	Change in substantial holding from AEF

4-Jul-2017	Change of Director's Interest Notice - JMcBrayer

4-Jul-2017	Change of Director's Interest Notice - VGould

4-Jul-2017	Change of Director's Interest Notice - D Heaney

30-Jun-2017	Appendix 3B Final

28-Jun-2017	CYC Entitlement Offer Closed

28-Jun-2017	CYC Notification of Shortfall

14-Jun-2017	CYC Entitlement Offer Booklet

5-Jun-2017	Letter to Ineligible Shareholders

5-Jun-2017	Letter to Eligible Shareholders

5-Jun-2017	Appendix 3B

5-Jun-2017	Cleansing Statement

5-Jun-2017	Entitlement Offer

2-Jun-2017	Response to ASX query on Appendix 3Y

1-Jun-2017	CYC - Positive Results of China Clinical Trial

31-May-2017	Change of Director's Interest Notice

12-May-2017	CYC May 2017 Investor Presentation

9-May-2017	Announcement of buy-back - Appendix 3C

9-May-2017	Results of Meeting

9-May-2017	Managing Director's Address to Shareholders

9-May-2017	Chairman's Address to Shareholders

9-May-2017	CYC 2017 AGM Presentation

8-May-2017	Final share buy-back notice - Appendix 3F

19-Apr-2017	Appendix 3B

7-Apr-2017	Notice of Annual General Meeting/Proxy Form

3-Apr-2017	Initial Director's Interest Notice

29-Mar-2017	CYC Board Changes

28-Mar-2017	CYC Appendix 4G

17-Mar-2017	Change in substantial holding from CVC

9-Mar-2017	Becoming a substantial holder - AACCF (Amended)

6-Mar-2017	CYC 2016 Financial Year Results Investor Presentation

1-Mar-2017	Ceasing to be a substantial holder - Lloyds (Amended)

27-Feb-2017	Cyclopharm Amended 2016 Preliminary Financial Report

22-Feb-2017	Dividend/Distribution - CYC

22-Feb-2017	Preliminary Final Report

17-Feb-2017	Becoming a substantial holder - AACCF

17-Feb-2017	Ceasing to be a substantial holder - Lloyds

6-Feb-2017	CYC 2016 PRELIMINARY HEADLINE UPDATE-RECORD RESULTS

1-Feb-2017	Release Date of 2016 Full Year Preliminary Financial Results

25-Nov-2016	Change of Director's Interest Notice

23-Nov-2016	CYC Achieves USFDA Agreement For Technegas Trial Design

31-Oct-2016	Change of Company Address

20-Oct-2016	Becoming a substantial holder from AEF

19-Oct-2016	Cyclopharm CEO Microcap Investment Conference Presentation

13-Oct-2016	Cyclopharm Business Update on Significant Milestones

7-Oct-2016	Chairman to Stand Down Temporarily

29-Aug-2016	CYC Share Registry Details

24-Aug-2016	Cyclopharm Limited 1H2016 Results Investor Presentation

19-Aug-2016	Dividend/Distribution - CYC

29-Jul-2016	CEO Presentation at BioShares BioTech Summit 2016

26-Jul-2016	Appendix 3B LTIP

21-Jul-2016	Cyclopharm Investor Presentation 21 July 2016

14-Jul-2016	CYC Strengthens Mgt Depth and Expands Clinical Expertise

28-Jun-2016	Change of Director's Interest Notice

28-Jun-2016	Change of Director's Interest Notice

27-Jun-2016	CYC Signs Agreement with the Canadian Association of Nuc Med

21-Jun-2016	Trading Update & Record Technegas Order Received from China

30-May-2016	Change of Share Registry address

11-May-2016	Announcement of buy-back - Appendix 3C

11-May-2016	Board Changes / Appendix 3Z

11-May-2016	Results of Annual General Meeting

11-May-2016	Managing Director's Report

11-May-2016	Managing Director's AGM Presentation

11-May-2016	Chairman's Address to Shareholders

10-May-2016	Cyclopharm to Proceed Independently with FDA Trials

18-Apr-2016	Appendix 4G

8-Apr-2016	Notice of Annual General Meeting/Proxy Form

17-Mar-2016	Cyclopharm Limited Investor Presentation

24-Feb-2016	Dividend/Distribution - CYC

24-Feb-2016	Strong Technegas Earnings Underpin Record Profit

24-Feb-2016	Preliminary Final Report

29-Jan-2016	Technegas COPD Trial Update

31-Dec-2015	Cyclopharm receives insurance settlement

31-Dec-2015	Cyclopharm receives insurance settlement

26-Nov-2015	Response to ASX query re Appendix 3Y

26-Nov-2015	Change of Director's Interest Notice

5-Nov-2015	Change of Director's Interest Notice

26-Oct-2015	Change of Director's Interest Notice

22-Oct-2015	Change in substantial holding from CVC

22-Oct-2015	Change of Director's Interest Notice

19-Oct-2015	Change of Director's Interest Notice

14-Oct-2015	Cyclopharm Pays Maiden Dividend

12-Oct-2015	Change of Director's Interest Notice

12-Oct-2015	Cyclopharm Launches World-First Nuclear Medicine Technology

7-Oct-2015	CYC Investor Presentation 7 October 2015

6-Oct-2015	Change of Director's Interest Notice

1-Oct-2015	Change of Director's Interest Notice

25-Sep-2015	Change of Director's Interest Notice

24-Sep-2015	Change of Director's Interest Notice

21-Sep-2015	Change of Director's Interest Notice

18-Sep-2015	Change in substantial holding from CVC

17-Sep-2015	Change of Director's Interest Notice

14-Sep-2015	Managing Director's Address to Investors

14-Sep-2015	Cyclopharm signs Term Sheet with Jubilant Draximage

27-Aug-2015	Dividend/Distribution - CYC

26-Aug-2015	Cyclopharm Unveils Inaugural Dividend

27-Jul-2015	CYC Investor Presentation July 2015

14-Jul-2015	Change of Director's Interest Notice

14-Jul-2015	Appendix 3B

10-Jul-2015	Change of Share Registry Name

26-May-2015	Results of Meeting

26-May-2015	Managing Director's Report

26-May-2015	Managing Director's AGM Presentation

26-May-2015	Chairman's Address to Shareholders

24-Apr-2015	Notice of Annual General Meeting/Proxy Form

12-Mar-2015	Investor Presentation

19-Feb-2015	Cyclopharm Reports Record Profit

19-Feb-2015	Preliminary Final Report

4-Feb-2015	Response to ASX Query

29-Jan-2015	Change of Director's Interest Notice

29-Jan-2015	Change of Director's Interest Notice

21-Jan-2015	Change of Share Registry address

27-Nov-2014	Form 484 - cancellation of Long Term Incentive Plan shares

27-Nov-2014	Form 484 Cancellation of Long Term Incentive Plan shares

16-Sep-2014	Update on Cyclotron Facility

2-Sep-2014	Appendix 3B

26-Aug-2014	Results of Mediation

14-Jul-2014	Change of Director's Interest Notice

20-Jun-2014	Cyclotron Facility Suffers Significant Water Damage

22-May-2014	Results of Meeting

22-May-2014	Managing Director's Report

22-May-2014	Chairman's Address to Shareholders

22-May-2014	Managing Director's AGM Presentation

15-May-2014	Chairman Reinstated

22-Apr-2014	Notice of Annual General Meeting/Proxy Form

31-Mar-2014	2013 Annual Report

28-Mar-2014	Cyclopharm to cease Cyclotron commercial operations

25-Mar-2014	Change of Director's Interest Notice

20-Mar-2014	Change of Director's Interest Notice

6-Mar-2014	Amended Appendix 3X

5-Mar-2014	Change of Director's Interest Notice

28-Feb-2014	Preliminary Final Report

23-Dec-2013	Change of Director's Interest Notice

25-Oct-2013	Japanese Regulatory Approval received

24-Oct-2013	Chairman to Stand Down Temporarily

21-Oct-2013	Change of Director's Interest Notice

17-Oct-2013	Letter to shareholders

14-Oct-2013	Change of Director's Interest Notice

19-Sep-2013	Change of Director's Interest Notice

16-Sep-2013	Director Appointment/Resignation

12-Sep-2013	Change of Director's Interest Notice

10-Sep-2013	Change of Director's Interest Notice

9-Sep-2013	Change of Director's Interest Notice

29-Aug-2013	Change of Director's Interest Notice

28-Aug-2013	2013 Half Yearly Report and Accounts

15-Aug-2013	Change of Director's Interest Notice

22-Jul-2013	Change of Director's Interest Notice

18-Jul-2013	Change of Director's Interest Notice

11-Jul-2013	Change of Director's Interest Notice

1-Jul-2013	Change of Director's Interest Notice

24-Jun-2013	Change of Director's Interest Notice

13-Jun-2013	Change of Director's Interest Notice

6-Jun-2013	Change of Director's Interest Notice

6-Jun-2013	MMI Research Revolutionises The Study of Ancient Artefacts

15-May-2013	Results of Meeting

15-May-2013	Managing Director's AGM Presentation

15-May-2013	Managing Director's Report

15-May-2013	Chairman's Address to Shareholders

3-May-2013	Change in substantial holding

2-May-2013	Technegas May Facilitate Earlier Diagnosis of COPD

18-Apr-2013	Cyclopharm Develops New Nuclear Medicine Technology

15-Apr-2013	Notice of Annual General Meeting/Proxy Form

4-Apr-2013	Change of Director's Interest Notice

2-Apr-2013	Form 484 - cancellation of Long Term Incentive Plan shares

28-Mar-2013	Annual Report to shareholders

26-Mar-2013	Change of Director's Interest Notice

26-Feb-2013	Preliminary Final Report

27-Dec-2012	Change in substantial holding

18-Dec-2012	Change of Director's Interest Notice

18-Dec-2012	Change of Director's Interest Notice

14-Dec-2012	Despatch of Holding Statements

14-Dec-2012	Appendix 3B Rights Issue

23-Nov-2012	Rights Issue - Despatch of Offer Documents

19-Nov-2012	Technegas Clinical Trial - First Patient Enrolled

9-Nov-2012	Entitlement and Acceptance Form

9-Nov-2012	Offer Booklet

9-Nov-2012	Cleansing Notice

9-Nov-2012	Appendix 3B

9-Nov-2012	Letter to Ineligible Shareholders

9-Nov-2012	Letter to Eligible Shareholders

9-Nov-2012	Renounceable Issue

6-Nov-2012	Change of Director's Interest Notice

6-Nov-2012	Change of Director's Interest Notice

6-Nov-2012	Change of Director's Interest Notice

6-Nov-2012	Appendix 3B

6-Nov-2012	Change of Director's Interest Notice

20-Sep-2012	Change in substantial holding

30-Aug-2012	Half Yearly Report and Accounts

28-Jun-2012	Cyclopharm Files Claim Against ANSTO

8-Jun-2012	Update on Share Consolidation

28-May-2012	AGM Presentation Audio Broadcast

24-May-2012	Results of Annual General Meeting

24-May-2012	Managing Director's Report

24-May-2012	Chairman's Address

24-May-2012	AGM Presentation

23-Apr-2012	Notice of Annual General Meeting/Proxy Form

4-Apr-2012	ANSTO Subsidiary in breach of Competitive Neutrality Rules

27-Mar-2012	Annual Report to shareholders

5-Mar-2012	Director Appointment/Resignation

29-Feb-2012	Preliminary Final Report

13-Feb-2012	Change in substantial holding

28-Dec-2011	Change in substantial holding

19-Dec-2011	MUH becomes Shareholder in CYC Imaging Joint Venture

19-Dec-2011	Change of Director's Interest Notice

19-Dec-2011	Change of Director's Interest Notice

13-Dec-2011	Cyclopharm Receives Approval from United States FDA

12-Dec-2011	Correction - Number of Issued Shares

9-Dec-2011	Rights Issue - Despatch of Holding Statements

6-Dec-2011	Completion of Rights Issue and Notice of Under Subscriptions

18-Nov-2011	Entitlement and Acceptance Form

18-Nov-2011	Offer Booklet for Renounceable Rights Issue

17-Nov-2011	Cleansing Notice

4-Nov-2011	Unmarketable Parcel Sale Facility

4-Nov-2011	Appendix 3B

4-Nov-2011	Letter to Ineligible Shareholders

4-Nov-2011	Letter to Eligible Shareholders

4-Nov-2011	Renounceable Rights Issue and Sale of Unmarketable Parcels

3-Nov-2011	Renewal of Debt Facility with National Australia Bank

27-Sep-2011	Amended Change of Director's Interest Notice

23-Sep-2011	Change of Director's Interest Notice

31-Aug-2011	Half Yearly Report and Accounts

29-Jul-2011	Trading Update

27-Jul-2011	Director Appointment/Resignation

27-Jun-2011	Change in substantial holding

20-Jun-2011	Change of Registered Office Address

6-Jun-2011	Change in substantial holding

2-Jun-2011	AGM Presentation Audio Broadcast

26-May-2011	AGM Presentation

26-May-2011	Managing Director's Report

26-May-2011	Chairman's Address to Shareholders

5-May-2011	Initial Director's Interest Notice

29-Apr-2011	Director Appointment/Resignation

18-Apr-2011	Notice of General Meeting/Proxy Form

25-Mar-2011	Company Secretary Appointment/Resignation

25-Mar-2011	Annual Report to shareholders

28-Feb-2011	Preliminary Final Report

22-Feb-2011	Clinical Protocol Approval from US FDA

24-Dec-2010	Diversity Policy

24-Dec-2010	Share Trading Policy

16-Dec-2010	Cyclopet sells commercial FDG doses

13-Dec-2010	Change of Director's Interest Notice

3-Dec-2010	Cyclopet receives TGA License

16-Nov-2010	Change in substantial holding

31-Aug-2010	Half Yearly Report and Accounts

6-Jul-2010	Company Update

26-May-2010	Change of Director`s Interest Notice

25-May-2010	Regulatory Approval in China

24-May-2010	2010 AGM Presentation - Audio Broadcast

20-May-2010	Results of Meeting

20-May-2010	Chairman`s Address

20-May-2010	Managing Director`s Presentation

20-May-2010	AGM Presentation

30-Apr-2010	Change in substantial holding

15-Apr-2010	Notice of General Meeting/Proxy Form

18-Mar-2010	2009 Annual Report

25-Feb-2010	Preliminary Final Report

17-Dec-2009	Change of Director`s Interest Notice

11-Dec-2009	Cyclopharm settles claim for US$1.8m

25-Nov-2009	Change in substantial holding from CVC

12-Nov-2009	Change of Director`s Interest Notice

9-Nov-2009	Cyclotron delivered to Macquarie University Hospital

19-Oct-2009	Change of Director`s Interest Notice

14-Oct-2009	Response to an ASX Query - Director`s Interest Notices

6-Oct-2009	Change of Director`s Interest Notice

29-Sep-2009	Change of Director`s Interest Notice

24-Sep-2009	Change of Director`s Interest Notice

27-Aug-2009	2009 Half Yearly Report and Accounts

3-Aug-2009	CYC enters into Medical Imaging JV- Audio Broadcast

29-Jul-2009	Cyclopharm enters into Medical Imaging Joint Venture

30-Jun-2009	Change of Director`s Interest Notice

9-Jun-2009	Change of Director`s Interest Notice

25-May-2009	2009 AGM Presentation - Audio Broadcast

21-May-2009	Results of Meeting

21-May-2009	Chairman`s Address

21-May-2009	Managing Director`s Presentation

21-May-2009	AGM Presentation

28-Apr-2009	Company Update

20-Apr-2009	Notice of General Meeting/Proxy Form

26-Mar-2009	2008 Annual Report

17-Mar-2009	Full Year Presentation - Audio Broadcast

17-Mar-2009	Change of Director`s Interest Notice

3-Mar-2009	Full Year Presentation

3-Mar-2009	Final Director`s Interest Notice

26-Feb-2009	Preliminary Final Report

20-Feb-2009	Profit Upgrade

19-Feb-2009	Resignation of Director

21-Jan-2009	Change in substantial holding

13-Jan-2009	Change in substantial holding from CVC

22-Dec-2008	Lodgement of application to sell Technegas in United States

22-Dec-2008	Company Update

4-Dec-2008	Change of Director`s Interest Notice

4-Dec-2008	Change of Director`s Interest Notice

4-Dec-2008	Change of Director`s Interest Notice

2-Dec-2008	Change of Director`s Interest Notice

2-Dec-2008	Change of Director`s Interest Notice

28-Nov-2008	Allotment of Rights Issue Shares

21-Nov-2008	Closure of Rights Issue

30-Oct-2008	Amendment to Dispatch Rights Issue Offer Document

30-Oct-2008	Rights Issue - Dispatch Offer Document

30-Oct-2008	Rights Issue - Offer Document

30-Oct-2008	Rights Issue - Cleansing Statement

17-Oct-2008	Amended Appendix 3B

17-Oct-2008	Amended Rights Issue Timetable

16-Oct-2008	Appendix 3B

16-Oct-2008	Announcement of Offer

26-Sep-2008	Change in substantial holding

24-Sep-2008	Investor Presentation - Audio Broadcast

17-Sep-2008	Investor Presentation

22-Aug-2008	Half Year Presentation

22-Aug-2008	2008 Half Yearly Report and Accounts

16-Jul-2008	Government expands PET approved indications

5-Jun-2008	Initial Director`s Interest Notice

5-Jun-2008	Appendix 3B

5-Jun-2008	Change of Director`s Interest Notice

3-Jun-2008	Change in substantial holding

3-Jun-2008	Confirmation of appointment of new Managing Director

27-May-2008	2008 AGM Presentation - Audio Broadcast

21-May-2008	Cyclopharm receives regulatory approval in Brazil

20-May-2008	Change of Director`s Interest Notice

12-May-2008	Change of Director`s Interest Notice

2-May-2008	AGM Presentation

2-May-2008	Results of Meeting

28-Apr-2008	Change in substantial holding

2-Apr-2008	Change of Director`s Interest Notice

2-Apr-2008	Amended Appendix 3Y released 25 March 2008

28-Mar-2008	Change in substantial holding

26-Mar-2008	Notice of Annual General Meeting/Proxy Form

25-Mar-2008	Change of Director`s Interest Notice

25-Mar-2008	Change in substantial holding

19-Mar-2008	Annual Report to shareholders

14-Mar-2008	Cyclopharm Limited achieves a major milestone in Sydney

6-Mar-2008	Full Year Result and Company Update - Audio Broadcast

29-Feb-2008	Preliminary Final Report

1-Feb-2008	Cyclopharm makes its first sale in Russia

25-Jan-2008	Director Appointment/Resignation

7-Jan-2008	Cyclopharm achieves a major milestone

3-Jan-2008	Regulatory Approval in Italy

17-Oct-2007	Change in substantial holding from CVC

16-Oct-2007	Change of Director`s Interest Notice

18-Sep-2007	Change of Director`s Interest Notice

28-Aug-2007	Half Year Presentation

28-Aug-2007	2007 Half Yearly Report and Accounts

13-Aug-2007	Change of Director`s Interest Notice

10-Aug-2007	Change in substantial holding from CVC

2-Aug-2007	Change in substantial holding from CVC

29-Jun-2007	Change in substantial holding

29-Jun-2007	Appendix 3B

13-Jun-2007	Change of Director's Interest Notice

9-May-2007	Managing Directors AGM Presentation

9-May-2007	Minutes of AGM

9-May-2007	Notice of Annual General Meeting

2-Apr-2007	2006 Annual Report

26-Feb-2007	Preliminary Final Report

13-Feb-2007	Becoming a substantial holder

12-Feb-2007	Initial Director's Interest Notice

12-Feb-2007	Initial Director's Interest Notice

12-Feb-2007	Initial Director's Interest Notice

12-Feb-2007	Initial Director's Interest Notice

12-Feb-2007	Initial Director's Interest Notice

22-Jan-2007	Constitution

19-Jan-2007	Becoming a substantial holder

19-Jan-2007	Becoming a substantial holder

19-Jan-2007	Becoming a substantial holder

18-Jan-2007	Becoming a substantial holder from CVC

18-Jan-2007	Audio Broadcast

18-Jan-2007	Amended Media Release

17-Jan-2007	Media Release

17-Jan-2007	Amended notice re Admission to Official List

17-Jan-2007	Admission to Official List

17-Jan-2007	Appendix 1A: ASX Listing application and agreement

16-Jan-2007	Statement from Directors

16-Jan-2007	CYC - Interim Report June 2006

16-Jan-2007	CYC - Financial Report 2004

16-Jan-2007	ASX Circular: Commencement of Official Quotation

16-Jan-2007	Distribution Schedule

16-Jan-2007	Top 20 shareholders

16-Jan-2007	Financial Report 31 December 2005

16-Jan-2007	Financial Report December 2003

2-Jan-2007	Prospectus

2-Jan-2007	Supplementary Disclosure Document